Assessment and incorporation of in vitro correlates to pharmacokinetic outcomes in antibody developability workflows

• Váldodahkkit: Tushar Jain (Dahkki), Bianka Prinz (Dahkki), Alexander Marker (Dahkki), Alexander Michel (Dahkki), Katrin Reichel (Dahkki), Valerie Czepczor (Dahkki), Sylvie Klieber (Dahkki), Wei Sun (Dahkki), Sagar Kathuria (Dahkki), Sevim Oezguer Bruederle (Dahkki), Christian Lange (Dahkki), Lena Wahl (Dahkki), Charles Starr (Dahkki), Alessandro Masiero (Dahkki), Lindsay Avery (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

In vitro assessments for the prediction of pharmacokinetic (PK) behavior of biotherapeutics can help identify corresponding liabilities significantly earlier in the discovery timeline. This can minimize the need for extensive early in vivo PK characterization, thereby reducing animal usage and optim...